Get the Stockscreener App
0.9172
2.43%
-0.0228
Matinas Biopharma Holdings Inc stock is traded at $0.9172, with a volume of 14,981.
It is down -2.43% in the last 24 hours and up +13.57% over the past month.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.
See More
Previous Close:
$0.94
Open:
$0.9389
24h Volume:
14,981
Relative Volume:
0.07
Market Cap:
$4.48M
Revenue:
-
Net Income/Loss:
$-21.13M
P/E Ratio:
-0.1915
EPS:
-4.79
Net Cash Flow:
$-16.95M
1W Performance:
-2.63%
1M Performance:
+13.57%
6M Performance:
+44.44%
1Y Performance:
+472.53%
1-Day Range:
$0.9116
$0.9389
1-Week Range:
$0.8803
$0.942
52-Week Range:
$0.09
$4.49
Matinas Biopharma Holdings Inc Stock (MTNB) Company Profile
Name
Matinas Biopharma Holdings Inc
Sector
Industry
Phone
908-443-1860
Address
1545 Route 206 South, Suite 302, Bedminster, NJ
Compare MTNB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTNB
Matinas Biopharma Holdings Inc
|
0.9172 | 4.48M | 0 | -21.13M | -16.95M | -4.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Matinas Biopharma Holdings Inc Stock (MTNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-26-20 | Resumed | Piper Sandler | Overweight |
| Jan-27-20 | Initiated | Piper Sandler | Overweight |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Jan-09-20 | Initiated | Aegis Capital | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Matinas Biopharma Holdings Inc Stock (MTNB) Latest News
MTNB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Kalkine Matinas BioPharma Surges Amid NYSE Composite Market Momentum - Kalkine Media
Matinas Biopharma (NYSE:MTNB) Trading 5.7% Higher – Here’s Why - Defense World
Matinas Biopharma (NYSE:MTNB) versus Marker Therapeutics (NASDAQ:MRKR) Head to Head Review - Defense World
Matinas BioPharma amends bylaws, updates on officer agreements By Investing.com - Investing.com Canada
Matinas BioPharma Amends Bylaws and Sets Annual Meeting - TipRanks
Matinas BioPharma amends bylaws, updates on officer agreements - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Matinas Biopharma (NYSE:MTNB) Shares Down 2.6% – Here’s What Happened - Defense World
MTNB stock touches 52-week low at $0.48 amid sharp annual decline - Investing.com Australia
MTNB stock touches 52-week low at $0.48 amid sharp annual decline By Investing.com - Investing.com South Africa
Matinas BioPharma secures shareholder nods on key proposals By Investing.com - Investing.com Australia
Matinas BioPharma secures shareholder nods on key proposals - Investing.com
Matinas Biopharma Delays 10-K Filing - TipRanks
Matinas Biopharma (NYSE:MTNB) Shares Down 6.6% – Should You Sell? - Defense World
Matinas BioPharma Chairman Eric Ende Resigns -March 17, 2025 at 05:08 am EDT - MarketScreener
Matinas BioPharma announces board chairman’s departure By Investing.com - Investing.com Australia
Matinas BioPharma announces board chairman’s departure - Investing.com
Matinas Biopharma Holdings Eric Ende Resigns As Chairman Of Matinas Biopharma -March 14, 2025 at 05:48 pm EDT - Marketscreener.com
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
Silicon Valley - Financial Content
Matinas Biopharma Holdings, Inc. to Host Earnings Call - ACCESS Newswire
12 Health Care Stocks Moving In Friday's Pre-Market SessionArtiva Biotherapeutics (NASDAQ:ARTV) - Benzinga
Matinas Biopharma Announces Agreement For The Acquisition Of Preferred Stock And Appointment Of Dr. Robin L. Smith To The Board Of Directors - Marketscreener.com
Matinas BioPharma Announces Agreement for the Acquisition - GlobeNewswire
Biotech Deal Alert: Matinas BioPharma Lands Critical $3.3M Investment While Strengthening Leadership - StockTitan
Matinas BioPharma announces board member retirement - MSN
Matinas BioPharma announces board member retirement By Investing.com - Investing.com South Africa
Matinas BioPharma Holdings, Inc. to Host Earnings Call - ACCESS Newswire
Matinas Biopharma Appoints Evelyn D’An as Director and Audit Committee Chair - Armenian Reporter
Matinas BioPharma Appoints Evelyn D’An to Board - citybiz
Matinas BioPharma Holdings, Inc. Appoints Evelyn D?An to Board of Directors as an Independent Director and Chair of the Audit Committee - Marketscreener.com
Matinas Biopharma Appoints Evelyn D'An To Board Of Directors As Audit Committee Chair - Marketscreener.com
Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair - The Manila Times
Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair - GlobeNewswire
Matinas BioPharma announces board member resignation - MSN
Matinas BioPharma announces board member resignation By Investing.com - Investing.com South Africa
Matinas Biopharma Holdings Inc Stock (MTNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):